The catabolism of glycosaminoglycans begins with endohydrolysis of polysaccharides to oligosaccharides followed by the sequential action of an array of exoenzymes to reduce these oligosaccharides to monosaccharides and inorganic sulfate. In a lysosomal storage disorder known as mucopolysaccharidosis I, caused by a deficiency of the exohydrolase alpha-l-iduronidase, fragments of two different glycosaminoglycans, dermatan sulfate and heparan sulfate, have been shown to accumulate. Oligosaccharides isolated from the urine of a mucopolysaccharidosis I patient using anion exchange and gel filtration chromatography were identified as di-, tri-, tetra-, penta-, and hexasaccharides using electrospray ionization-tandem mass spectrometry and shown to...
Dermatan sulphate (DS) is a sulphated glycosaminoglycan (GAG) that is widely distributed as proteogl...
Glycosaminoglycans (GAGs) are distributed in the whole body and play a variety of important physiolo...
Therapeutic development and monitoring require demonstration of effects on disease phenotype. Howeve...
The catabolism of glycosaminoglycans begins with endo-hydrolysis of polysaccharides to oligosacchari...
Within cells, dermatan sulfate (DS) and heparan sulfate (HS) are degraded in two steps. The initial ...
Heparan sulfate is a linear glycosaminoglycan with considerable structural diversity that binds a my...
Heparan sulfate (HS) catabolism begins with endo-degradation of the polysaccharide to smaller HS oli...
Heparan sulfate (HS) catabolism begins with endo-degradation of the polysaccharide to smaller HS oli...
The mucopolysaccharidoses are a family of genetic diseases involving faulty degradation of one or mo...
Impaired degradation of glycosaminoglycans (GAGs) with consequent intralysosomal accumulation of und...
Impaired degradation of glycosaminoglycans (GAGs) with consequent intralysosomal accumulation of und...
A combination of anion-exchange chromatography and 30-40% gradient polyacrylamide gel electrophoresi...
Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by deficiency of the l...
Glycosaminoglycans in urine from patients representing the major different mucopolysaccharidoses wer...
Mucopolysaccharidosis I is a lysosomal storage disorder caused by a deficiency of the lysosomal hydr...
Dermatan sulphate (DS) is a sulphated glycosaminoglycan (GAG) that is widely distributed as proteogl...
Glycosaminoglycans (GAGs) are distributed in the whole body and play a variety of important physiolo...
Therapeutic development and monitoring require demonstration of effects on disease phenotype. Howeve...
The catabolism of glycosaminoglycans begins with endo-hydrolysis of polysaccharides to oligosacchari...
Within cells, dermatan sulfate (DS) and heparan sulfate (HS) are degraded in two steps. The initial ...
Heparan sulfate is a linear glycosaminoglycan with considerable structural diversity that binds a my...
Heparan sulfate (HS) catabolism begins with endo-degradation of the polysaccharide to smaller HS oli...
Heparan sulfate (HS) catabolism begins with endo-degradation of the polysaccharide to smaller HS oli...
The mucopolysaccharidoses are a family of genetic diseases involving faulty degradation of one or mo...
Impaired degradation of glycosaminoglycans (GAGs) with consequent intralysosomal accumulation of und...
Impaired degradation of glycosaminoglycans (GAGs) with consequent intralysosomal accumulation of und...
A combination of anion-exchange chromatography and 30-40% gradient polyacrylamide gel electrophoresi...
Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by deficiency of the l...
Glycosaminoglycans in urine from patients representing the major different mucopolysaccharidoses wer...
Mucopolysaccharidosis I is a lysosomal storage disorder caused by a deficiency of the lysosomal hydr...
Dermatan sulphate (DS) is a sulphated glycosaminoglycan (GAG) that is widely distributed as proteogl...
Glycosaminoglycans (GAGs) are distributed in the whole body and play a variety of important physiolo...
Therapeutic development and monitoring require demonstration of effects on disease phenotype. Howeve...